Loading company…
Precipio Diagnostics develops hematopathology diagnostic kits and culture media for detecting blood cancers in clinical laboratories.
Founded in 2011 in New Haven, US, Precipio Diagnostics sells diagnostic products for blood cancers, including molecular kits such as the Bloodhound BCR-ABL1 and MPN panels, to clinical laboratories and healthcare institutions. It received USD 1.8 mn of Series B funding in October 2013, led by Connecticut Innovations with Enhanced Capital, Ironwood Capital and Kuzari Group. The firm has completed three deals to date.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in